• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Chief Executive Officer Wallace Eli M.

    10/6/25 4:22:15 PM ET
    $BBOT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BBOT alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Wallace Eli M.

    (Last) (First) (Middle)
    BRIDGEBIO ONCOLOGY THERAPEUTICS, INC.
    256 EAST GRAND AVENUE, SUITE 104

    (Street)
    SOUTH SAN FRANCISCO CA 94080

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    BridgeBio Oncology Therapeutics, Inc. [ BBOT ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    X Officer (give title below) Other (specify below)
    Chief Executive Officer
    3. Date of Earliest Transaction (Month/Day/Year)
    10/02/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Stock Option (Right to Buy) $12.44 10/02/2025 A 1,614,400 (1) 10/01/2035 Common Stock 1,614,400 $0 1,614,400 D
    Explanation of Responses:
    1. 1/48th of the shares subject to such option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of October 2, 2025, subject to the Reporting Person's continuous service to the Issuer on each such date.
    /s/ Aaron Chan, Attorney-in-Fact 10/06/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $BBOT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BBOT

    DatePrice TargetRatingAnalyst
    2/11/2026$23.00Buy
    Stifel
    1/9/2026$24.00Outperform
    Raymond James
    12/5/2025$20.00Overweight
    Morgan Stanley
    9/17/2025$25.00Outperform
    Leerink Partners
    9/15/2025$27.00Buy
    H.C. Wainwright
    8/15/2025$21.00Overweight
    Piper Sandler
    More analyst ratings

    $BBOT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Stifel initiated coverage on BridgeBio Oncology Therapeutics with a new price target

    Stifel initiated coverage of BridgeBio Oncology Therapeutics with a rating of Buy and set a new price target of $23.00

    2/11/26 7:51:34 AM ET
    $BBOT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Raymond James initiated coverage on BridgeBio Oncology Therapeutics with a new price target

    Raymond James initiated coverage of BridgeBio Oncology Therapeutics with a rating of Outperform and set a new price target of $24.00

    1/9/26 9:02:41 AM ET
    $BBOT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Morgan Stanley initiated coverage on BridgeBio Oncology Therapeutics with a new price target

    Morgan Stanley initiated coverage of BridgeBio Oncology Therapeutics with a rating of Overweight and set a new price target of $20.00

    12/5/25 8:44:53 AM ET
    $BBOT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BBOT
    SEC Filings

    View All

    SEC Form 424B3 filed by BridgeBio Oncology Therapeutics Inc.

    424B3 - BridgeBio Oncology Therapeutics, Inc. (0001869105) (Filer)

    1/7/26 7:15:58 AM ET
    $BBOT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B3 filed by BridgeBio Oncology Therapeutics Inc.

    424B3 - BridgeBio Oncology Therapeutics, Inc. (0001869105) (Filer)

    1/7/26 7:12:21 AM ET
    $BBOT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 8-K filed by BridgeBio Oncology Therapeutics Inc.

    8-K - BridgeBio Oncology Therapeutics, Inc. (0001869105) (Filer)

    1/7/26 7:09:49 AM ET
    $BBOT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BBOT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

    SOUTH SAN FRANCISCO, Calif., Feb. 11, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc., or BBOT (NASDAQ:BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced it awarded inducement grants on February 10, 2026 under BBOT's 2025 Inducement Plan as a material inducement to the employment of two individuals hired by BBOT in January 2026. The employees received, in the aggregate, non-qualified stock options to purchase 65,350 shares of BBOT common stock, par value $0.0001 per share, with an exercise price of $10.84 per share, the closing price of BBOT's common stock as reported by Nasdaq on the effective date of the grant, which wil

    2/11/26 4:05:00 PM ET
    $BBOT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

    SOUTH SAN FRANCISCO, Calif., Jan. 13, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc., or BBOT (NASDAQ:BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced it awarded an inducement grant on January 10, 2026 under BBOT's 2025 Inducement Plan as a material inducement to the employment of an individual hired by BBOT in December 2025. The employee received non-qualified stock options to purchase 129,090 shares of BBOT common stock, par value $0.0001 per share, with an exercise price of $13.19 per share, the closing price of BBOT's common stock as reported by Nasdaq on the effective date of the grant, which will vest 1/4 on the f

    1/13/26 4:05:00 PM ET
    $BBOT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BBOT Announces New Clinical Data Advancing Its Portfolio of Three Innovative and Differentiated RAS and PI3Kα Pipeline Programs

    BBO-8520 monotherapy in patients with KRASG12C non-small cell lung cancer (NSCLC) showed a 65% objective response rate (ORR) and a 66% 6-month progression-free survival (PFS), with 83% of patients eligible for 6-month follow-up remaining on treatment for ≥6 months, alongside a potentially differentiated safety profile. Encouraging early efficacy signals were seen in patients with KRASG12C and STK11 and/or KEAP1 co-mutants, where all five initial patients achieved partial response.BBO-8520 in combination with pembrolizumab, at active dose levels, demonstrated promising efficacy data and a distinct, differentiated safety profile. A favorable liver safety profile was observed compared with pemb

    1/7/26 7:00:00 AM ET
    $BBOT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BBOT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Executive Officer Wallace Eli M.

    4 - BridgeBio Oncology Therapeutics, Inc. (0001869105) (Issuer)

    1/5/26 7:22:35 PM ET
    $BBOT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chief Executive Officer Wallace Eli M.

    4 - BridgeBio Oncology Therapeutics, Inc. (0001869105) (Issuer)

    12/12/25 7:04:11 PM ET
    $BBOT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Bridgebio Pharma Llc acquired 784,720 shares (SEC Form 4)

    4 - BridgeBio Oncology Therapeutics, Inc. (0001869105) (Issuer)

    10/16/25 5:54:33 PM ET
    $BBOT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BBOT
    Leadership Updates

    Live Leadership Updates

    View All

    BBOT Reports Third Quarter 2025 Financial Results and Update on Corporate Progress

    BBOT debuted as a publicly traded company focused on optimized target coverage for patients with tumors driven by RAS and PI3Kα and a synergistic portfolio that is designed to enable targeted KRAS combinations Advanced three ongoing Phase 1 clinical trials, with clinical data readouts from each program expected in 2026Cash runway expected to fund BBOT operations into 2028Appointed industry veteran Uneek Mehra as Chief Financial Officer SOUTH SAN FRANCISCO, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. ("BBOT") (NASDAQ:BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today reported financial results for the third quar

    11/12/25 4:05:00 PM ET
    $BBOT
    $HLXB
    Biotechnology: Pharmaceutical Preparations
    Health Care